Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Poop pills show promise for gut disease

NCT ID NCT05998213

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether fecal transplants from healthy donors could help people with ulcerative colitis, a chronic condition causing inflammation in the colon. 85 participants received either donor or their own stool via tubes and enemas. The goal was to see if donor transplants could reduce symptoms and heal the gut lining, offering a new way to manage this disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

85 people

The number who actually took part.

Started

Jun 2020

Finished

Dec 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 70 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥18 and \<70 * Ability to give informed consent * Established ulcerative colitis with known involvement of the left colon according to the Lennard-Jones criteria * Partial mayo score of ≥ 3 and calprotectin \> 250 * Full Mayo score 5-9 * Endoscopic Mayo score of ≥2 in either the rectum or sigmoid upon screening sigmoidoscopy * Stable dose of thiopurines or , 5-ASA, or budesonide in preceding 8 weeks. * Stable dose of budesonide in preceding 2 weeks. * Prednisone use ≤15mg/day in preceding 2 weeks with a mandatory taper of 5 mg per week starting from week 4. * Women need to use reliable contraceptives during participation in the study * Alkaline phosphatase \> 1.5 x ULN in the subgroup of PSC/UC patients. Exclusion Criteria: * Condition leading to profound immunosuppression * For example: HIV, infectious diseases leading to immunosuppression, bone marrow malignancies * Use of systemic chemotherapy * Child-Pugh B liver cirrhosis * Anti-TNFα treatment in preceding 2 months * Vedolizumab treatment in preceding 2 months * Tofacitinib treatment in preceding 2 months * Ustekinumab treatment in preceding 2 months * Cyclosporine treatment in preceding 4 weeks * Use of Methotrexate in preceding 2 months * Prednisolone dose \> 15 mg/day in preceding 2 weeks * Use of topical therapy in preceding 2 weeks * Life expectancy \< 12 months * Difficulty with swallowing * Use of systemic antibiotics in preceding 4 weeks * Use of probiotic treatment in preceding 4 weeks * Positive stool cultures for common enteric pathogens (Salmonella, Shigella, Yersinia, Campylobacter, enteropathogenic e coli) * Positive C. Difficile stool test * Positive dual faeces test for pathogenic parasites e.g. Dientamoeba histolytica, Giardia Lamblia, Dientamoeba fragilis, Blastocystis hominis only if microscopically many or very many blastocysts are seen. * Positive serological test for HIV * History of surgery: * presence of a pouch * presence of stoma * Known intra-abdominal fistula * Pregnancy or women who give breastfeeding * Vasopressive medication, icu stay * Signs of ileus, diminished passage * Allergy to macrogol or substituents, eg peanuts, shellfish * Known allergy to iv gadolinium in the subgroup of patients who would be scheduled for MRI liver * Crohn's disease * Subject who has any conditions that in the opinion of the investigator, would compromise the safety of the subject or the quality of the data and is an unsuitable candidate for the study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Ulcerative colitis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Amsterdam University Medical Center

    Amsterdam, North Holland, 1061BK, Netherlands

More trials for these conditions

Other studies related to the condition(s) this trial covers.